WHO ARE WE?

LIRIC PRESIDENT

  LLUÍS MASANA  (coordination and representative tasks)

  • Medical Advisor in Lipid Metabolism and Health.
  • Emeritus Professor of Medicine at Universitat Rovira i Virgili (Reus, SPAIN).
  • Past-President of the Spanish Society of Arteriosclerosis (1999-2004)
  • Former Member of the Executive Committee of the European Lipoprotein Club (1990-1994).
  • Former Member of the Executive Committee of the European Atherosclerosis Society (2009-2013). Current member of EAS Ethical Committee.
  • Member of the EAS Lipid Clinic Network.
  • Full Member of the Royal Academy of Medicine of Catalonia since 2002.
  • President of the Catalan Society and Units Network of Lipids and Atherosclerosis
  • Author of more than 400 publications on lipids and arteriosclerosis

Lipid and Arteriosclerosis Research Unit (URLA)


URLA is a well-established research group dedicated to the study of lipid metabolism disorders and their relationship with cardiovascular diseases.

Its main research areas include:

  • Familial hypercholesterolemia
  • Lipoprotein metabolism
  • Arteriosclerosis and cardiovascular risk
  • Genetics and epigenetics of dyslipidemias

The unit combines basic and clinical research with the aim of improving the diagnosis, prevention, and treatment of lipid-related metabolic diseases.

Head of the unit: Josep Ribalta Vives
Members: Joan Carles Vallvé Torrente, Josefa Girona Tell, Montserrat Guardiola Guionnet, Ricardo Rodríguez Calvo, Yaiza Esteban Romero, Roser Rosales Ribas, Helena Banús

Vascular Medicine and Metabolism Unit (UVASMET)

UVASMET is a clinical and research unit focused on the diagnosis and treatment of lipid metabolism disorders and hypertension, with a special emphasis on the prevention of cardiovascular diseases.

Its main activities include:

  • Care for patients with dyslipidemia and high cardiovascular risk
  • Clinical studies and trials in metabolic diseases
  • Advanced lipid metabolism analysis
  • Identification of biomarkers and genetic studies

Its goal is to translate scientific advances into clinical practice, improving patients’ cardiovascular health.

Head of the unit: Daiana Ibarretxe Gerediaga
Members: Ana González-Lleó, Cèlia Rodríguez Borjabad , Èrica Cunillera, Meritxell Royuela.

Biosfer Teslab SL

Biosfer Teslab SL is a biotechnology company focused on the development and application of advanced technologies for lipid metabolism analysis, with special emphasis on lipoprotein characterization and cardiovascular risk assessment.

Its main activities include:

  • Development of innovative methods based on nuclear magnetic resonance (NMR) for lipid analysis
  • Advanced lipoprotein analysis services (Liposcale®)
  • Collaboration with research centers and hospitals in scientific projects
  • Knowledge and technology transfer to the clinical and biomedical fields
  • Applied data analysis and machine learning for predictive model development in lipidomics and cardiovascular risk assessment.

Its goal is to provide high-precision tools to improve diagnosis, cardiovascular risk stratification, and clinical decision-making in metabolic diseases.

Company lead: Núria Amigó Grau

Members: Sara Samino Gené, Daniel Rodríguez Romeu, Neus Martínez Micaelo, Lydia Cabau, Pol Torné Charlez, Víctor Chausse Calbet, Cristina Zincu, Jara Ballestín